• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Polyrizon Ltd.

    7/24/25 4:15:49 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PLRZ alert in real time by email
    S-8 1 ea0249817-s8_polyrizon.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on July 24, 2025

    Registration No. 333-              

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8
    REGISTRATION STATEMENT

    UNDER
    THE SECURITIES ACT OF 1933

     

    Polyrizon Ltd.

    (Exact name of registrant as specified in its charter)

     

    Not Applicable
    (Translation of Registrant’s name into English)

     

    State of Israel   2834   Not Applicable
    (State or other jurisdiction of
    incorporation or organization)
      (Primary Standard Industrial
    Classification Code Number)
      (I.R.S. Employer
    Identification Number)

     

    5 Ha-Tidhar Street

    Raanana, 4366507, Israel

    Tel: +972-9-3740120

    (Address, including zip code, and telephone number, including
    area code, of Registrant’s principal executive offices)

     

    Polyrizon Ltd.

    Amended and Restated Equity Incentive Plan

    (Full title of the plan)

     

    Puglisi & Associates

    850 Library Ave., Suite 204

    Newark, DE 19711

    Tel: (302) 738-6680
    (Name, address, including zip code, and telephone number,
    including area code, of agent for service)

     

    Copies to:

     

    David Huberman, Esq.

    Greenberg Traurig, P.A.

    One Azrieli Center

    Round Tower, 30th floor

    132 Menachem Begin Rd

    Tel Aviv 6701101

    Telephone: 312.364.1633

      Shachar Hadar, Adv.
    Meitar | Law Offices
    16 Abba Hillel Silver Rd.
    Ramat Gan 5250608, Israel
    Tel: +972-3-610-3100

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☐
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Polyrizon Ltd. (the “Company” or the “Registrant”) previously filed with the Securities and Exchange Commission (the “Commission”) a registration statement on Form S-8 (File No. 333-284410) to register under the Securities Act of 1933, as amended (the “Securities Act”) (i) 246,129 ordinary shares, no par value per share (the “Ordinary Shares”), of the Registrant issuable upon the exercise of options outstanding under the Polyrizon Ltd. Amended and Restated Equity Incentive Plan (the “Plan”) and (ii) 553,871 Ordinary Shares of the Registrant reserved for issuance under the Plan. The previously-filed registration statement is referred to herein as the “Prior Registration Statement.”

     

    On May 27, 2025, the Company effected a one-for-two-hundred-and-fifty (1-for-250) reverse share split of its Ordinary Shares (the “Reverse Split”) which reduced the number of Ordinary Shares reserved under the Plan to 3,200 Ordinary Shares. On July 20, 2025, the Company’s Board of Directors, approved an amendment to the Plan in order to increase the number of Ordinary Shares reserved under the Plan to 1,200,000 Ordinary Shares.

     

    In accordance with General Instruction E to Form S-8, the Company is filing this registration statement on Form S-8 solely to register an additional 1,196,800 Ordinary Shares which may be issued under the Plan over and above the number of Ordinary Shares issuable pursuant to the Plan that were registered under the Prior Registration Statement. Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statement are hereby incorporated by reference in their entirety, with the exception of Items 3 and 8 of Part II of such Prior Registration Statement, each of which is amended and restated in its entirety herein.

     

     

     

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE 

     

    The following documents filed with the Securities and Exchange Commission (the “SEC”) by Polyrizon Ltd. (the “Registrant”) are incorporated herein by reference.

     

    (1)The Registrant’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 11, 2025;

     

    (2)The Registrant’s Reports on Form 6-K filed with the SEC on  March 10, 2025, March 13, 2025, March 14, 2025, March 25, 2025, March 27, 2025, April 1, 2025, April 2, 2025, April 11, 2025, April 17, 2025, April 25, 2025, May 1, 2025, May 1, 2025, May 14, 2025, May 19, 2025, May 21, 2025, May 22, 2025, May 23, 2025, June 12, 2025, June 30, 2025, July 15, 2025 and July 22, 2025 to the extent expressly incorporated by reference into the Registrant’s effective registration statements filed by the Registrant under the Securities Act); and

     

    (3)the description of the Registrant’s Ordinary Shares contained under the heading “Item 1. Description of Registrant’s Securities to be Registered” in the Registrant’s registration statement on Form 8-A, as filed with the SEC on October 21, 2024, including any subsequent amendment or any report filed for the purpose of updating such description.

     

    In addition to the foregoing, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and all reports on Form 6-K subsequently filed by the Registrant which state that they are incorporated by reference herein, prior to the filing of a post- effective amendment which indicates that all securities offered hereunder have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents and reports.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein, or in any subsequently filed document which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    ITEM 8. EXHIBITS

     

    See attached Exhibit Index.

     

    II-1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Raanana, Israel, on July 24, 2025.

     

      POLYRIZON LTD.
         
      By: /s/ Tomer Izraeli
      Name:  Tomer Izraeli
      Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each of the undersigned officers and directors of Polyrizon Ltd. hereby severally constitutes and appoints Tomer Izraeli and Nir Ben Yosef, the true and lawful attorney with full power to them, to sign for the undersigned and in his or her name in the capacities indicated below, any and all amendments, including the post-effective amendments, to this Registration Statement, and generally to do all such things in the undersigned’s name and behalf in such capacities to enable Polyrizon Ltd. to comply with the applicable provisions of the Securities Act of 1933, as amended, and all rules and regulation thereunder, and all requirements of the Securities and Exchange Commission, and each of the undersigned hereby ratifies and confirms all that said attorneys or any of them shall lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signatures   Title   Date
             
    /s/ Tomer Izraeli   Chief Executive Officer, Director   July 24, 2025
    Tomer Izraeli   (Principal Executive Officer)    
             
    /s/ Nir Ben Yosef   Chief Financial Officer   July 24, 2025
    Nir Ben Yosef   (Principal Financial and Accounting Officer)    
             
    /s/ Oz Adler   Chairman of the Board of Directors   July 24, 2025
    Oz Adler        
             
    /s/ Asaf Itzhaik   Director   July 24, 2025
    Asaf Itzhaik        
             
    /s/ Liat Sidi   Director   July 24, 2025
    Liat Sidi        
             
    /s/ Yehonatan Zalman Vinokur   Director   July 24, 2025
    Yehonatan Zalman Vinokur        
             
    /s/ Liron Carmel   Director   July 24, 2025
    Liron Carmel        

     

    II-2

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Polyrizon Ltd., has signed this Registration Statement on July 24, 2025.

     

      Puglisi & Associates
       
      Authorized U.S. Representative
         
      By: /s/ Donald J. Puglisi
      Name:  Donald J. Puglisi               
      Title: Managing Director

     

    II-3

     

     

    EXHIBIT INDEX

     

    Exhibit Number   Description of Exhibit
    3.1   Amended and Restated Articles of Association of the Registrant (filed as Exhibit 3.1 to the Registrant’s Registration Statement on Form F-1 (File No. 333-286849) as filed with the Securities and Exchange Commission on April 30, 2025, and incorporated herein by reference).
    5.1*   Opinion of Meitar | Law Offices, Israeli counsel to the Registrant, as to the legality of the securities being registered
    23.1*   Consent of Consent of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, an independent registered public accounting firm
    23.2*   Consent of Meitar | Law Offices, Israeli counsel to the Registrant (included in Exhibit 5.1)
    24.1*   Power of Attorney (included on the signature page of this Registration Statement)
    99.1#   Polyrizon Ltd. Amended and Restated Equity Incentive Plan (filed as Exhibit 99.1 to the Registrant’s Registration Statement on Form S-8 (File No. 333-284410) as filed with the Securities and Exchange Commission on January 22, 2025, and incorporated herein by reference).
    107*   Filing Fee Table

     

    * Filed herewith.
    # English translation of original Hebrew document.

     

     

     

    II-4

     

    Get the next $PLRZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLRZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLRZ
    SEC Filings

    View All

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    9/19/25 8:39:02 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    9/17/25 4:15:26 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    9/4/25 4:15:17 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

    Ra'anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced the submission of its full pre-submission (Pre-Sub) package to the U.S. Food and Drug Administration (FDA) for its PL-14 product, designed to help individuals suffering from nasal allergies. The submission includes comprehensive documentation covering manufacturing plans, clinical development strategies, and regulatory pathways. This submission represents a significant progress in Polyrizon's regulatory strategy, paving the way for potential marketing clearance and addressing a critical

    9/19/25 8:15:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

    Ra'anana, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for early allergen contact—reinforcing the product's potential as a barrier-forming treatment for allergic rhinitis. The evaluation was led by Professor Fabio Sonvico from the Department

    9/12/25 7:26:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Regains Compliance with Nasdaq Listing Requirements

    Ra'anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced that it has received formal confirmation from the Hearings Advisor (the "Hearings Advisor") of the Office of the General Counsel of the Nasdaq Hearings Panel (the "Nasdaq Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with all applicable listing requirements. In a letter dated August 13, 2025, the Hearings Advisor informed the Company that it has demonstrated compliance with the minimum bid price requirement for continued listing set

    8/14/25 8:14:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRZ
    Leadership Updates

    Live Leadership Updates

    View All

    Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

    Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product developmen

    12/19/24 7:22:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

    Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions. Asaf Azulay brings over 20 years of extensive experience in the medical devices industry, with expertise in leading quality teams and i

    12/13/24 6:25:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care